Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel...

Por Bondarenko, Igor, Gladkov, Oleg A, Elsaesser, Reiner, Buchner, Anton, Bias, Peter
Publicado em 2013

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

Por Volovat, Constantin, Bondarenko, Igor M, Gladkov, Oleg A, Elsässer, Reiner, Buchner, Anton, Bias, Peter, Müller, Udo
Publicado no Springerplus (2015)

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Por Clemens, Michael R., Gladkov, Oleg A., Gartner, Elaina, Vladimirov, Vladimir, Crown, John, Steinberg, Joyce, Jie, Fei, Keating, Anne
Publicado no Breast Cancer Res Treat (2014)